Chronic Spontaneous Urticaria Market Size in the 7MM is Projected to Enhance at a Significant CAGR by 2036, Estimates DelveInsight

The market dynamics for Chronic Spontaneous Urticaria (CSU) is witnessing significant growth driven by the rising prevalence of chronic inflammatory skin disorders, increasing diagnosis rates, improved disease awareness, and higher treatment-seeking behavior among patients with persistent hives and angioedema. Growing demand for targeted biologics, better access to specialty care, and expanding use of advanced immunomodulatory therapies are further supporting market expansion. Additionally, the launch of emerging therapies such as barzolvolimab (Celldex Therapeutics), remibrutinib (Novartis), dupilumab (Sanofi/Regeneron), and others will further fuel the market.

DelveInsight's "Chronic Spontaneous Urticaria Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Chronic Spontaneous Urticaria Market Share @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the Chronic Spontaneous Urticaria Market Report
• The market size for Chronic Spontaneous Urticaria in the leading markets is expected to grow significantly by 2036.
• The United States accounted for the highest Chronic Spontaneous Urticaria treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
• According to the findings, the 7MM accounted for a substantial number of diagnosed prevalent Chronic Spontaneous Urticaria cases in 2025, with cases expected to rise during the forecast period.
• In 2025, the US accounted for the highest number of Chronic Spontaneous Urticaria diagnosed prevalent cases, followed by EU4 and the UK.
• The leading Chronic Spontaneous Urticaria Companies such as Novartis, Genentech/Roche, Sanofi, Regeneron, Celldex Therapeutics, Jasper Therapeutics, and others.
• Promising Chronic Spontaneous Urticaria Pipeline Therapies such as remibrutinib, barzolvolimab, briquilimab, dupilumab and others.

Stay ahead in the Chronic Spontaneous Urticaria Therapeutics Market with DelveInsight's Strategic Report @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Chronic Spontaneous Urticaria?
Chronic Spontaneous Urticaria (CSU) is a chronic inflammatory skin disorder characterized by the spontaneous appearance of itchy wheals (hives), swelling (angioedema), or both for six weeks or longer without an identifiable external trigger. The condition is primarily driven by mast cell and basophil activation leading to histamine release and recurrent symptoms that can significantly impair sleep, work productivity, emotional well-being, and quality of life. While second-generation H1-antihistamines are used as first-line treatment, many patients remain symptomatic and require biologics or other advanced therapies for disease control.

Chronic Spontaneous Urticaria Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of Chronic Spontaneous Urticaria
• Gender-specific Cases of Chronic Spontaneous Urticaria
• Age-specific Cases of Chronic Spontaneous Urticaria
• Severity-specific Cases of Chronic Spontaneous Urticaria
• Treated Cases of Chronic Spontaneous Urticaria
• Eligible Cases for Biologic Therapy

Download the report to understand which factors are driving Chronic Spontaneous Urticaria Epidemiology trends @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Chronic Spontaneous Urticaria Marketed Drugs

XOLAIR (omalizumab): Genentech/Roche and Novartis
XOLAIR is a monoclonal anti-IgE antibody approved for patients with Chronic Spontaneous Urticaria inadequately controlled with H1 antihistamines and remains a major treatment option across global markets.

DUPIXENT (dupilumab): Sanofi and Regeneron
DUPIXENT has expanded its immunology portfolio with growing relevance in urticaria treatment strategies and is expected to strengthen the biologics segment.

Chronic Spontaneous Urticaria Drugs and Companies
• Novartis: Remibrutinib
• Celldex Therapeutics: Barzolvolimab
• Jasper Therapeutics: Briquilimab

To learn more about Chronic Spontaneous Urticaria treatment guidelines, visit @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving Chronic Spontaneous Urticaria Market
• Rising disease prevalence and diagnosis rates: Increased awareness among physicians and patients is leading to earlier diagnosis and treatment of Chronic Spontaneous Urticaria.
• High unmet need in antihistamine-refractory patients: A considerable proportion of patients remain uncontrolled despite standard antihistamine therapy, creating demand for effective targeted treatments.
• Strong biologics adoption: The success of anti-IgE therapy and emergence of novel mast-cell targeted drugs are accelerating market growth.
• Improved understanding of disease biology: Advances in immunology and mast cell signaling pathways are enabling next-generation precision therapies.
• Active clinical pipeline and regulatory support: Multiple late-stage pipeline therapies and favorable regulatory pathways are encouraging continued investment and innovation.

Recent Developments in the Chronic Spontaneous Urticaria Market
• During 2025, Novartis continued advancing remibrutinib in late-stage clinical development for Chronic Spontaneous Urticaria, highlighting its potential as an oral BTK inhibitor for patients with inadequate disease control.
• In 2025, Celldex Therapeutics reported continued progress for barzolvolimab, a KIT-targeting monoclonal antibody, demonstrating durable symptom control and favorable clinical outcomes in Chronic Spontaneous Urticaria studies.

Scope of the Chronic Spontaneous Urticaria Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Chronic Spontaneous Urticaria Companies: Novartis, Genentech/Roche, Sanofi, Regeneron, Celldex Therapeutics, Jasper Therapeutics and others.
• Chronic Spontaneous Urticaria Pipeline Therapies: XOLAIR, DUPIXENT, remibrutinib, barzolvolimab, briquilimab and others.
• Chronic Spontaneous Urticaria Market Dynamics: Chronic Spontaneous Urticaria Market Drivers and Barriers
• Chronic Spontaneous Urticaria Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Chronic Spontaneous Urticaria Drugs in development @ https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Chronic Spontaneous Urticaria Market Report Introduction
2. Executive Summary for Chronic Spontaneous Urticaria
3. SWOT Analysis of Chronic Spontaneous Urticaria
4. Chronic Spontaneous Urticaria Patient Share (%) Overview at a Glance
5. Chronic Spontaneous Urticaria Market Overview at a Glance
6. Chronic Spontaneous Urticaria Background and Overview
7. Chronic Spontaneous Urticaria Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Spontaneous Urticaria
9. Chronic Spontaneous Urticaria Current Treatment and Medical Practices
10. Chronic Spontaneous Urticaria Unmet Needs
11. Chronic Spontaneous Urticaria Emerging Therapies
12. Chronic Spontaneous Urticaria Market Outlook
13. Country-Wise Chronic Spontaneous Urticaria Market Analysis (2022-2036)
14. Chronic Spontaneous Urticaria Market Access and Reimbursement of Therapies
15. Chronic Spontaneous Urticaria Market Drivers
16. Chronic Spontaneous Urticaria Market Barriers
17. Chronic Spontaneous Urticaria Appendix
18. Chronic Spontaneous Urticaria Report Methodology
19. DelveInsight Capabilities
20. Disclaimer

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.